September/October 2012

Use of a simple model developed by the patient advocacy community could facilitate valuable dialogue between the FDA and people with chronic conditions.

HIV is of interest among many in managed care. This paper focuses on the costs and demographic characteristics associated with new HIV therapy initiators.

Patients with diabetic peripheral neuropathy taking L-methylfolate, pyridoxal-5'-phosphate, and methylcobalamin (MPM) had lower all-cause hospitalization risk and healthcare costs than patients not taking MPM.

The OneTouch VerioIQ Meter uses pattern recognition technology for self-monitoring of blood glucose, a key part of treatment management in patients with type 1 and type 2 diabetes.

Retrospective analysis of a population meeting criteria for the ACCORD lipid trial supported adjunct fenofibrate in patients with reduced low-density lipoprotein cholesterol and elevated triglycerides.

Results from Eisai Inc's online national survey of cancer patients, published in the 2012 Eisai Oncology Digest, highlight financial concerns of cancer treatment and their impact on treatment adherence.

Patients, payers, providers, and employers are affected by misdiagnosis, undertreatment, and inappropriate management of migraine.

Conference coverage of the 2012 meeting of the American Diabetes Association.

How do we define and measure value in terms of healthcare?